Objective: To describe the association of specific medication classes with driving outcomes and provide clinical recommendations. Data Sources: The MEDLINE and EMBASE databases were searched for articles published from January 1973 to June 2013 on classes of medications associated with driving impairment. The search included outcome terms such as automobile driving, motor vehicle crash, driving simulator, and road tests. Study Selection and Data Extraction: Only English-language articles that contained findings from observational or interventional designs with ≥ 10 participants were included in this review. Cross-sectional studies, case series, and case reports were excluded. Data Synthesis: Driving is an important task and activity for the majority of adults. Some commonly prescribed medications have been associated with driving impairment measured by road performance, driving simulation, and/or motor vehicle crashes. This review of 30 studies identified findings with barbiturates, benzodiazepines, hypnotics, antidepressants, opioid and nonsteroidal analgesics, anticonvulsants, antipsychotics, antiparkinsonian agents, skeletal muscle relaxants, antihistamines, anticholinergic medications, and hypoglycemic agents. Additional studies of medication impact on sedation, sleep latency, and psychomotor function, as well as the role of alcohol, are also discussed. Conclusions: Psychotropic agents and those with central nervous system side effects were associated with measures of impaired driving performance. It is difficult to determine if such associations are actually a result of medication use or the medical diagnosis itself. Regardless, clinicians should be aware of the increased risk of impaired driving with specific classes of medications, educate their patients, and/ or consider safer alternatives.
Introduction
More than 6000 FDA-approved medications are currently on the market. 1 With so many agents available and medication consumption on the rise in an aging demographic, the incidence of adverse drug events is a growing concern. It has been estimated that 20% of Medicare beneficiaries have 5 or more chronic conditions, and more than 50% are on 5 or more medications. 2 Polypharmacy, or the superfluous use of medications without clinical indication, may easily be overlooked by clinicians.
Medications may affect the visual, cognitive, and/or motor abilities needed for safe driving. Human factors determine how smoothly we are able to execute and transition between stages of the driver information processing modelperception, decision, and reaction. 3 According to this model, fitness to drive is contingent on our eyes, brain, and musculoskeletal system working in harmony. 4 Ophthalmic medications may cause blurred vision or dizziness; some medications can cause tremor, impaired coordination, or myopathy; and others can affect the central nervous system by causing sedation, confusion, or dizziness.
Cognitive tests are commonly used to assess driving ability, such as Trail Making Test Parts A and B (TMT-A and TMT-B, respectively), 5 maze completion tests, 6 and the Freud Clock Drawing Test. 5 Tests of cognition may be useful in predicting a patient's executive function, route planning, or visuospatial aptitude. Popular tools also include the Digit Symbol Substitution Test (DSST), 7 which assesses visual scanning, attention, psychomotor speed, information processing, and general executive function, important skills when roadside signs must be read or obstacles recognized quickly. Sedation can be measured on a variety of subjective scales but is often documented in the form of the Mean Sleep Latency Test. 8 520882A OPXXX10.1177/1060028014520882Annals of PharmacotherapyHetland and Carr Medications associated with motor vehicle crashes may also be characterized as having the potential to impair driving performance. Perhaps the most cited reference in the realm of medications and driving, LeRoy and Morse 9 examined 33 519 cases involving motor vehicle collisions, with individuals matched by age and gender to more than 100 000 controls. Medications more prevalent in case participants were assigned a calculated odds ratio (OR) indicating the increased crash rate relative to patients not taking that medication. For example, the use of belladonna alkaloids revealed an OR of 1.85, conferring an 85% increase in crash rate. 9 Numerous studies have also associated the use of certain agents with poor performance on real or simulated driving evaluations. The State Department of Motor Vehicles often uses the road test as the final or major arbitrator to determine licensing. Thus, many authorities recognize the performance-based road test as the de facto standard. 10 Brake reaction time becomes important in assessing a patient's ability to quickly recognize road hazards and stop the vehicle. 11 Another measurement-the standard deviation of lateral position (SDLP)-indicates how well the vehicle is controlled and kept in the center of the lane. 12 Not surprisingly, medications associated with impaired driving have been classified as potentially driver-impairing (PDI) medications. 13 There is little agreement on what should be labeled a PDI medication or whether there is enough evidence to suggest that clinicians modify their prescribing behaviors toward any specific subclass. The primary goal of this paper was to review studies that link driving impairment with prescription medications and to enlighten clinicians of those that might warrant special attention. Prescribing and monitoring recommendations are provided.
Criteria for Selection and Assessment of the Literature
Statistically significant results from the LeRoy and Morse 9 study were used as the foundation for this review. Medication classes with a strong association, which we defined as an OR of ≥1.40, were further investigated. The MEDLINE and EMBASE databases were searched for English-language articles published from January 1973 to July 2013. Search terms included humans, barbiturate, benzodiazepine, narcotic, opioid, hypnotic, hypoglycemic, anticholinergic, NSAID (nonsteroidal anti-inflammatory drug), antihistamine, antipsychotic, anxiolytic, antiepileptic, antiparkinsonian, skeletal muscle relaxant, antiplatelet, antithrombotic, antihypertensive, antidepressant, potential driver impairment, automobile driving, motor vehicle crash, driving simulator, and road tests. Publications with findings from observational or interventional studies were included, whereas those describing results of cross-sectional studies, case series, or case reports were excluded. Studies conducted using fewer than 10 participants were also excluded.
Data Synthesis
In all, 25 classes of medications were associated with at least a 40% increased crash risk in the LeRoy and Morse 9 study. (The OR mentioned within each section refers to the results from LeRoy and Morse 9 unless otherwise referenced.) A review of the literature corroborated this association for several of these classes, which have been rearranged into the following 18 sections for consistency. Some sources presented notable contradictory findings, which are included as well. Thirty reference studies are discussed ( Table 1 ).
Psychotropic Medications
Barbiturates. Barbiturates have myriad outpatient indications-anxiety, seizure, insomnia-and are also utilized as fast-acting anesthetics to sedate patients undergoing surgery. Examples include phenobarbital, amobarbital, and secobarbital. Barbiturates enhance the natural effects of γ-aminobutyric acid, which can lead to significant sedation and diminished coordination. 14 Use of these agents has been associated with motor vehicle collisions by an OR of 7.5; in other words, drivers taking barbiturates showed an increased crash likelihood that was 7.5 times higher than that for drivers not taking these medications. 9 Apart from some very dated literature, rigorous studies on driving impairment with barbiturates are rare, demonstrating the obsolescence of these agents in an everevolving pharmaceutical market. Thankfully, safer alternatives exist.
Benzodiazepines (BZDs). Whereas LeRoy and Morse 9 showed that BZD use corresponds to double the risk of a motor vehicle crash, further studies have demonstrated that these agents cause measureable impairments in cognitive and motor function as well. 15 BZDs may cause severe respiratory depression and are thus subject to routine monitoring of vital signs. Other PDI side effects may include sedation, weakness, clumsiness, loss of balance, dizziness, and distorted vision. 14 Barbone and colleagues 16 observed more than a 2-fold higher risk of automobile collision with the use of anxiolytic BZDs, such as alprazolam and lorazepam. However, hypnotic BZDs such as flurazepam and temazepam did not show a statistically significant difference. 16 It is important to consider the approximate rate of elimination to schedule an appropriate regimen. BZDs with longer half-lives may invariably produce carryover effects beyond the dosing period. 17 For instance, midazolam has a half-life of 1 to 5 hours, whereas diazepam concentrations do not fall to 50% until after about 30 to 60 hours. 18 In SNRI, serotonin and norepinephrine reuptake inhibitor; HR, hazard ratio; NSAID, nonsteroidal antiinflammatory drug; ACE, angiotensin-converting enzyme; AED, antiepileptic drug; BRT, brake reaction time; IM, intramuscular; SIR, standardized incidence ratio; MDD, major depressive disorder; IRR, incidence rate ratio; ARR, adjusted rate ratio; MPR, medication possession ratio. general, a shorter acting BZD is preferred over one that may remain in the body for several days or be metabolized to active metabolites. Nighttime dosing with shorter-duration agents may lessen the chance of daytime PDI effects. Indeed, a 1997 study found increased risk of crash with the use of long-half-life BZDs (t ½ > 24 hours) but not with short-half-life BZDs. 19 A dose-dependent association is also worth mentioning. In a study of elderly Medicaid enrollees, the risk of motor vehicle crash was increased with BZD use but was even greater for those taking diazepam in excess of 20 mg/d. 20 Physicians should examine other therapeutic options first, and if a BZD is selected, it should be initiated at the lowest possible dose.
Non-BZD Hypnotics. Zolpidem, zaleplon, and eszopiclone have been around since the 1990s and have become a popular alternative to BZDs in managing sleep disorders. They still may produce dizziness and drowsiness and were shown to increase collision rate by 48% in the LeRoy and Morse study. 9 Zolpidem has gained attention for case reports of sleep walking, eating, and even driving during the night without recollection the next morning. In light of this "known risk," the FDA announced in May 2013 that it would require manufacturer labeling to indicate a lower recommended dose of zolpidem. For instance, the recommended dose of immediate-release products has been reduced from 10 to 5 mg for women. 21 The literature has associated zolpidem with both at-fault and non-at-fault collisions. The risk of motor vehicle accident appears to be greater in patients prescribed more than 10 mg/d. 22 A placebo comparison study examining zolpidem and zopiclone, the stereoisomer of eszopiclone, noted a quantitatively similar risk with both medications. This risk increased with younger age, perhaps as a consequence of reduced lifetime exposure compared with older patients taking the same medications. 23 Impairment with zopiclone was also seen in an earlier study using a battery of cognitive and driving assessments; this same study found 10-mg zaleplon to produce no impairment as compared with placebo. 24 Eszopiclone has been shown to improve both quality of sleep and sleep latency, but only in healthy volunteers did it cause statistically significant sedation. Insomnia patients were not any more drowsy with or without the medication, supporting the benefit of eszopiclone for patients who have trouble sleeping. 25 Ultimately, the literature designates no impairment with zaleplon, 24 no impairment with eszopiclone in patients with insomnia, 25 and an increased crash risk overall with use of zolpidem. 22 Perhaps the best option is to prescribe a non-BZD hypnotic at a low evening dose and to dissuade patients from driving during the initiation phase.
Tricyclic Antidepressants (TCAs). Although this class has been replaced by better-tolerated agents in the treatment of major depressive disorder, TCAs are still prescribed for neuropathic pain, certain anxieties, and menopausal symptoms. Medications include amitriptyline and imipramine, with active metabolites nortriptyline and desipramine, as well as doxepin. These agents can produce anticholinergic effects, orthostatic hypotension, and varying degrees of central depression and sedation. 14 Additionally, LeRoy and Morse 9 found a 41% greater crash likelihood with the use of a TCA.
Even higher values have been reported in other literature, ranging from a 220% to 230% risk. 20, 26 A convincing dose-dependent association was also noted, with patients using more than 125 mg/d of amitriptyline. 20 Iwamoto et al 27 discovered a correlation with plasma levels of amitriptyline and poor vehicle maneuvering via SDLP. Four hours following administration of 25-mg amitriptyline, individuals exhibited more lateral weaving and variation in car-following distance. 28 Brunnauer and colleagues 29 examined 100 patients treated with antidepressants and found that only 10% of TCA users passed a global driving ability test compared with patients on mirtazepine (50% pass rate). Patients receiving TCAs also performed worse on psychomotor and visual perception assessments, indicating that perhaps TCAs should be a last line of therapy when alternatives exist. 29 If a TCA must be prescribed, patients should be advised to avoid driving during initial use and after each dosage adjustment. 4 Selective Serotonin Reuptake Inhibitors (SSRIs). These agents are the most commonly prescribed class to treat depression and are gaining popularity in the pharmacotherapy of anxiety disorders. SSRIs include paroxetine, fluoxetine, citalopram and its enantiomer escitalopram, and sertraline. Common PDI effects are altered sleep architecture and tremor. 30 LeRoy and Morse 9 noted a motor vehicle crash OR of 1.59 with the use of SSRIs, slightly higher than the risk with TCAs by the same study. However, SSRIs were found to have an advantage over TCAs in tests of selective attention in a 2006 trial of patients with depression. 29 Wingen et al 31 reported increases in SDLP with the use of an SSRI or serotonin and norepinephrine reuptake inhibitor (SNRI) but did not identify a difference with either class individually. Similarly, crash rate per a Norwegian national registry was increased with SSRIs or venlafaxine, but again, these groups were combined and not assessed according to use of individual medication classes. 32 The same year, results of another randomized study showed no difference in SDLP between paroxetine and placebo. 28 In a meta-analysis, Ravera and colleagues 33 concluded that although data seem "unclear and conflicting," SSRIs only appear to pose a threat to driving when given at high doses. Because many clinicians favor SSRIs, patients should be educated about potential deleterious effects on driving and alertness.
Second-Generation and Related Antidepressants. Several antidepressants have been developed with structures and pharmacodynamic mechanisms that do not fit neatly into any previous antidepressant medication classes; these are the second-generation antidepressants. SNRIs include venlafaxine and duloxetine and have been associated with a 78% increase in crash rate. 9 However, no consistent or meaningful impact on driving behavior was observed in a blinded controlled trial of venlafaxine against placebo; SDLP and subject ratings of drowsiness did not significantly differ between groups. 34 Partial serotonin antagonists, trazodone and nefazodone, were found to be associated with a 90% higher chance of crash, whereas bupropion and mirtazapine demonstrated nonsignificant findings. 9 In a crossover trial comparing mirtazapine with placebo, driving performance was affected during the initial treatment period (days 1 to 7) with a lower 30-mg dose, but this effect did not remain for days 8 to 15 when participants were given 45 mg/d. 35 It is possible that adaptation or mirtazepine's inverse dose-dependent sedation may have played a role in this outcome. A recent study found that for a combined group of patients prescribed SSRIs, SNRIs, or partial serotonin antagonists, crash risk was increased by 10%, but this was significant only when a BZD had been coprescribed. 36 There is inconsistency in the literature regarding secondgeneration antidepressants. Thorough counseling should be provided to patients, and nighttime administration should be scheduled when the risk of sedation is high. As with most PDI medications, patients should monitor for side effects during initial treatment in order to observe potential impacts on driving. If the patient perceives the impairment as too severe, an alternate drug may be considered.
Analgesics
Opioid Analgesics. Although opioid analgesics are indeed sedating, they offer a number of additional PDI effects. Respiratory depression can occur, as with BZDs. Patients may also experience fatigue, lightheadedness, and miosis or pupillary constriction. 14 These side effects are ameliorated with extended use, although visual changes may persist. 37 Crash analysis data have shown that narcotics confer a 2.2 times higher risk, 9 although medication use was not classified as acute versus chronic. Injury and hospitalization for automobile crash, especially for women, have been associated with opioid use. 38 A 2012 cohort study noted a substantial impact on TMT-A and TMT-B in a combined group of BZDs, opioids, and antipsychotics, but it is difficult to parse out which specific class may have been responsible for this finding. 39 In 2000, Galski and colleagues 40 attempted to answer a common clinical question: Do chronic opioid users have the same high risk of impaired driving? Patients on chronic opioid therapy demonstrated better threat recognition braking accuracy, visuospatial ability, and DSST scores as well as an improved ability to follow directions when compared with other rehabilitated drivers (poststroke or post-brain injury) who had previously taken and passed the road test battery. 40 Perhaps continued use of opioid analgesics allows for physiological adaptation to their centrally depressive effects, making the risk for driving impairment greatest during initial therapy.
Fortunately, there are ways to mitigate risk of impaired driving. First, a combination product may be chosen to reduce the required dose for analgesia. Examples include oxycodone and hydrocodone, which may be formulated in smaller doses with acetaminophen. 14 Patients who are naïve to opioid analgesics should be started low and titrated slowly to an appropriate pain score. Prescribers might also advise patients against driving during the first 4 or 5 days after initiating or modifying the dose of an opioid analgesic. Patients should avoid other sedating products, such as firstgeneration antihistamines, BZDs, and alcohol. 4 If only acute therapy is required, advise temporary driving cessation during use.
Nonsteroidal Anti-inflammatory Drugs. NSAIDs are a frequent choice for relief of pain, inflammation, and fever. They are not often thought about as having an impact on driving and cognition, although drug monographs advise caution when driving or operating heavy machinery with the use of agents like ibuprofen, naproxen, and indomethacin. Dizziness, drowsiness, and blurred vision are possible PDI effects. LeRoy and Morse 9 found a 58% higher crash risk in patients taking NSAIDs, so the potential influence on driving should not be underemphasized.
McGwin and colleagues 41 reported a similar (70%) increase in at-fault crashes from a case-control study, a risk that was significantly greater when ACE inhibitors were given concomitantly. This could be explained by the pharmacodynamic interaction between these 2 classes of medications, or perhaps it is simply the result of medical illness (eg, congestive heart failure) requiring ACE inhibitor therapy. Unfortunately, the true relationship of NSAIDs with driving impairment is easily confounded by coadministration with other medications prescribed for pain. Whether we blame driving impairment on the medication or on the condition it treats, physicians should be wary when recommending an NSAID to patients with whom driving is already a concern.
Centrally Active Medications Antiepileptic Drugs (AEDs). Also known as anticonvulsants, AEDs include carbamazepine, phenytoin, valproate, gabapentin, topiramate, lamotrigine, ethosuximide, and others. Possible side effects include somnolence, slowed speech and psychomotor function, and mydriasis. 14 Use of anticonvulsants has been associated with a 97% increased collision rate, almost twice the probability of a crash. 9 However, some studies in epileptic patients have commented on the benefit of therapy. Preventing seizures on the road would certainly reduce the incidence of collision, so optimal therapy is key. Interestingly, Krauss et al 42 reported that having AED therapy switched or doses decreased was associated with a reduced crash incidence, indicating the need for careful monitoring and dose titration. A large multicenter study discovered higher crash rates in patients not taking their AEDs appropriately than in medication-adherent patients. 43 As some AEDs may be epileptogenic, the physician must prescribe a dose and frequency adequate to maintain nontoxic, therapeutic concentrations. As mentioned, a vigilant clinician is a great asset to monitor and fine-tune AED regimens, ensuring quality medication management and reduced danger of operating a motor vehicle.
Antipsychotics. Although some first-generation antipsychotics (FGAs) remain in use today, a newer class of secondgeneration antipsychotics (SGAs) has largely replaced them in the outpatient setting. These include but are not limited to aripiprazole, quetiapine, clozapine, and olanzapine. In addition to extrapyramidal symptoms, SGAs may cause sedation, visual disturbances, confusion, and orthostasis. 14 LeRoy and Morse 9 observed a 120% increase in crash rate with the use of SGAs, whereas findings for FGAs, such as haloperidol and fluphenazine, were nonsignificant. In contrast, quetiapine outperformed haloperidol in measures of psychomotor skill and was associated with fewer driving simulator accidents in hospitalized patients with schizophrenia prior to discharge. 44 Despite mixed findings in the literature, detailed patient counseling is advised when prescribing an antipsychotic of any kind.
Antiparkinsonian Agents. Medications used to manage Parkinson's disease include carbidopa and levodopa, pramipexole, ropinirole, entacapone, and amantadine, although others may be prescribed. Unfortunately, studies of antiparkinsonian effects on driving are scarce. Interpretation of such studies is often complicated by the presence of disease and ethical concerns with giving placebo. The majority of patients with Parkinson's disease already receive treatment, making it difficult or impossible to compare medicated with nonmedicated patients. Although our search turned up no rigorous driving studies of this medication class, we feel it still warrants a discussion of adverse events.
Patients taking antiparkinsonian agents have reported "sleep attacks"-sudden, unexpected lapses of attention and falling asleep. This may, in part, be a result of anticholinergic properties of certain agents like benztropine and trihexylphenidyl. 14 Montastruc et al 45 noted that more than 30% of patients on these medications reported experiencing a sleep attack. A recent study in Parkinson's patients examined the frequency of sleep attacks and found it highest when dopamine agonists were combined with levodopa. The highest risk with any single agent was with pramipexole, although ropinirole and ergot-containing agonists were also associated with sleep attacks. 46 Interviews with 3 movement disorder centers identified 8 patients involved in automobile accidents; all 8 had fallen asleep at the wheel during treatment with pramipexole. 47 Additionally, results from a 2009 blinded trial revealed that pramipexole reduced sleep latency over placebo with no subjective indication of sleepiness. No changes in time to sleep were observed with bromocriptine, however. 48 Fluctuating drug levels may also interfere with motor function, and some patients are affected by an "on/off" phenomenon. Thus, timing of driving trips in relation to medication peaks may become critical. Optimally, the drugs suppress involuntary gestures, but waxing and waning plasma levels may produce slowed or diminished voluntary movement with spastic, involuntary end-of-dose movements, a collective condition called dyskinesia. Naïve patients should be instructed to take the drug for about 5 days before driving, should they experience these effects. 4 Potential underlying effects of disease should not be disregarded. Compared with healthy controls, medically treated Parkinson's patients already exhibit suboptimal reactivity to stimuli while driving. 49 The benefits of antiparkinsonians to enhance driving ability must be highlighted; they have great potential to improve motor speed, gait, balance, rigidity, and tremor, deficits which could conceivably impede driving ability if untreated. (SMRs) . The LeRoy and Morse 9 study reported an OR of 2.09 for patients taking SMRs, attributable to PDI effects like drowsiness, ataxia, and blurred vision. 14 Carisoprodol was studied in 2011 using healthy individuals and was found to produce diminished psychomotor response with the DSST. Moreover, subjective sedation ratings were greater with carisoprodol at both 350and 700-mg doses. Overall perceived medication effect was high with 700-mg carisoprodol, but participants did not perceive an effect at the 350-mg dose, indicating a lack of effect discrimination. 50 Unfortunately, our search returned no studies of SMRs; however, forensic toxicology studies have reported an association with impairment and increased blood levels of these agents. 51, 52 Although we agree that these drugs should be considered PDI medications, additional studies are needed to confirm this relationship.
Skeletal Muscle Relaxants
Additional SMRs include baclofen, cyclobenzaprine, dantrolene, metaxalone, and tizanidine. In spite of the lack of non-PDI alternatives, patients being prescribed these medications need strict counseling on the dangers of driving during use.
Others
Antihistamines. First-generation antihistamines-diphenhydramine, doxylamine, hydroxyzine, and several othersare more lipophilic and can easily permeate the blood-brain barrier. Most second-generation antihistamines have been designed to eliminate sedating side effects; loratadine and fexofenadine do not contain label warnings against motor vehicle operation. Because of their hydrophilic nature, these medications remain in the periphery without a pronounced effect on wakefulness. Taking these medications at doses above what is recommended may, however, cause some of the medication to cross into the brain to cause PDI effects. 30 One second-generation antihistamine, cetirizine, has been associated with slight impairments. 53 Yanai et al 54 suggest that antihistamines be classified by their occupancy of central histamine receptors (H 1 R). When subjected to PET imaging in brain tissue, nonsedating antihistamines were classified as having an H 1 R occupancy of 0% to 20% and included fexofenadine, terfenadine, and 10-mg cetirizine. Less sedative agents were, notably, azelastine and 20-mg cetirizine. The most sedating antihistamines included chlorpheniramine and ketotifen.
Subjective symptoms of drowsiness, such as yawning or drooping eyelids, may not be apparent when effects on driving and psychomotor function occur. Authors of a placebocontrolled crossover study commented that drivers using sedating antihistamines may not perceive that they are under any sort of impairment. This same study found that individuals taking hydroxyzine had significantly slower brake reaction time than those given fexofenadine. 11 In a randomized controlled trial, those with a blood alcohol content (BAC) one-eighth the legal limit were able to better steer a vehicle simulator than those given 50 mg of diphenhydramine. 55 A double-blind crossover in healthy men also revealed a significant change in sleep latency with diphenhydramine as well as increased somnolence for ketotifen, cetirizine, and diphenhydramine but not for loratadine. 53 Driving-related deficits have been noted in a number of other studies, including increased SDLP with clemastine 3 to 4 hours following a morning dose. 56 An isomer of chlorpheniramine produced a similar effect 3 hours after the first dose, but this impairment was absent by the eighth day of treatment. 57 Patients should be prescribed a nonsedating antihistamine when indicated; otherwise, temporary driving cessation is recommended for patients during daytime use of a first-generation agent. 30 Cetirizine, although likely less impairing than first-generation antihistamines, should be reserved for drivers who have responded inadequately to loratadine and fexofenadine.
Intestinal and Antiemetic Agents. Treatment of emesis, intestinal spasticity, and abdominal cramping commonly includes the use of anticholinergic agents. Use of a natural belladonna or an antiemetic conferred a respective 85% and 63% increased crash risk in the LeRoy and Morse 9 study, whereas crash outcome data with other antispasmodics were nonsignificant. Belladonna alkaloids such as scopolamine, atropine, and hyoscyamine, along with other, newer muscarinic antagonists such as dicyclomine and glycopyrrolate, may cause PDI effects, including drowsiness, blurred vision, and delirium. 14 In a large randomized study, atropine demonstrated reduced performance on an attention test despite minimal subject reports of perceived impairment. Glycopyrrolate performed even worse, with lower scores on the attention test, poorer coordination, and longer time to complete coordination tasks. 58 A study in healthy male aviation pilots produced similar results with atropine, including significantly greater error in altitude control, control while turning, and tracking accuracy. 59 When possible, these medications are to be avoided, and newer agents should be attempted before prescribing a belladonna alkaloid.
Antiemetics prochlorperazine and droperidol have also been associated with poor performance in driving simulator studies. Betts et al 60 reported a longer time to complete the driving test and more cones hit by prochlorperazine users compared with those on placebo. Simulator driving test scores were also reduced following an intramuscular droperidol injection; fortunately, participants could perceive driving impairment 60% of the time when given droperidol but never with placebo. 61 Hypoglycemic Agents. Studies have shown that insulin, which can induce a hypoglycemic state, has been significantly associated with falls. 62 Symptoms of hypoglycemia are often patient specific but may include mental and visual problems as well as dizziness, shakiness, and lightheadedness. 14 LeRoy and Morse 9 stratified hypoglycemic medications by their physiological mechanisms of action: insulin (OR = 1.80), sulfonylureas (OR = 1.50), and bisguanides such as metformin (OR = 1.49). 14 Use of an insulin pump, which carries the risk of symptomatic hypoglycemia, has been associated with driving mishaps such as collision or being stopped for reckless driving. 63 Similar findings were published in 2006, where an increased crash rate was seen for insulin monotherapy and for dual treatment with a sulfonylurea and metformin. However, no effect was noted when insulin was combined with one of these medications or in patients taking a sulfonylurea or metformin alone. 64 Physicians must exercise caution when designing a diabetes regimen, especially in elderly drivers or individuals at high risk of hypoglycemia. In some cases, medications less associated with low blood sugar, such as exenatide or sitagliptin, may be preferred. Conditions of greater risk (eg, brittle diabetes with recurrent hypoglycemia) should alert clinicians to allow for a less tightly controlled regimen in patients still operating a motor vehicle.
Alcohol Effects
All patients should be encouraged to avoid or limit alcohol intake, especially when they expect to drive. Physicians have an opportunity and, arguably, a responsibility to counsel patients on the dangers of ethanol. Consumption of alcohol, in adequate doses, is lethal to nearly all living creatures. Humans are no exception. At lower BACs, the body suffers only mild impairment, with a lowered sense of inhibition and a decline in concentration and alertness.
Although the definition of moderate alcohol use varies among patients, typically no more than 1 alcoholic beverage (14 g) 65 should be ingested per day by a woman, with a limit of 2 for men. In patients who consume more than the recommended amount of alcohol, further depressive effects may be expected. Plasma levels rise, allowing more alcohol to cross the blood-brain barrier to access the central nervous system.
Health care professionals should discourage the intake of alcohol while driving or in combination with centrally active agents because it can exacerbate the PDI effects of certain medications. Alcohol augments and subsequently increases the risk of overdose with BZDs, causing further deficits in psychomotor function, respiration, and alertness. It may also trigger hypoglycemia induced by sulfonylureas and bisguanides, orthostasis by sympatholytic agents, and drowsiness by SMRs. 66 Yet another medication, ranitidine, blocks liver enzymes that metabolize alcohol as it arrives via the hepatic portal system, resulting in a more elevated BAC. 67 Several medications interact with ethanol and demand tailored counseling ( Table 2 ).
Limitations
Whereas the majority of the literature is based on retrospective vehicle crash claims, novel studies are beginning to investigate their relationship with practical, real-time impairments. As the definition of a PDI medication continues to evolve, more studies of medication use with driving simulators and road tests would be helpful in determining actual risks. Unfortunately, most current studies examine real patients and may present several biases. Reported PDI associations may be confounded by disease state and/or other medications and are highly susceptible to response and reporting bias by the individual.
Additionally, this review was conducted purely as a systematic literature search and did not involve inferential analysis. The methods used for this review were not exhaustive of the driving literature and should not be the sole consideration when recommending pharmacotherapy for motorists. An association with impaired driving does not necessarily imply causation because other factors may be at play, such as chronic disease, acute emotional or physical stress, and performance bias or the related Hawthorne effect.
Summary
Driving impairment was observed with medication use in numerous studies. These medications may create stress, frustration, and inconvenience when they seemingly control whether a patient can safely operate a vehicle. Although this article discusses several deleterious effects of medication use, positive outcomes should not be underestimated. Medications improve or stabilize many medical conditions, which may also enhance the ability to drive. The risk-tobenefit ratio must be evaluated for each patient before prescribing. As long as anticipated benefits outweigh risks of use, medications should be prescribed with clear, comprehensible, and individualized counseling. When alternatives are not an option, the lowest effective dose should be given, so that therapeutic efficacy is achieved while minimizing adverse outcomes on driving.
Driving has become an essential skill in today's society to facilitate work, social connectedness, and everyday life. Thus, the impact of medications on driving is an important consideration in designing a medication regimen. This literature review article, coupled with the availability of clinical trial data and drug monographs, should equip prescribers with the tools to make informed, ethical decisions in selecting medication therapy.
